Compare JAZZ & CPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | CPT |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.4B |
| IPO Year | 2007 | 1995 |
| Metric | JAZZ | CPT |
|---|---|---|
| Price | $202.48 | $104.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | ★ $217.57 | $115.28 |
| AVG Volume (30 Days) | 832.5K | ★ 999.3K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.03% |
| EPS Growth | N/A | ★ 136.00 |
| EPS | N/A | ★ 3.54 |
| Revenue | ★ $1,618,693,000.00 | $12,967,000.00 |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $7.68 | $2.60 |
| P/E Ratio | ★ N/A | $29.84 |
| Revenue Growth | N/A | ★ 81.69 |
| 52 Week Low | $105.00 | $96.53 |
| 52 Week High | $207.48 | $121.33 |
| Indicator | JAZZ | CPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 56.53 |
| Support Level | $194.77 | $100.63 |
| Resistance Level | $207.48 | $111.94 |
| Average True Range (ATR) | 5.09 | 2.32 |
| MACD | -0.29 | 0.46 |
| Stochastic Oscillator | 60.62 | 67.89 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.